vs
HACKETT GROUP, INC.（HCKT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是HACKETT GROUP, INC.的1.7倍（$127.1M vs $75.8M），再鼎医药同比增速更快（17.1% vs -4.4%），过去两年再鼎医药的营收复合增速更高（20.8% vs -0.9%）
哈克特集团是源自英国的男童服饰多渠道零售商，主营各类男士及男童服装与配饰，品牌于1983年在英国伦敦创立。截至2019年6月，该品牌在全球共开设160家门店，旗舰店坐落于伦敦萨维尔街14号，目前由黎巴嫩M1集团与美国L资本亚洲共同持有。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
HCKT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$75.8M
营收增速更快
ZLAB
高出21.5%
-4.4%
两年增速更快
ZLAB
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.8M | $127.1M |
| 净利润 | $5.6M | — |
| 毛利率 | 41.7% | 51.0% |
| 营业利润率 | 12.0% | -54.6% |
| 净利率 | 7.4% | — |
| 营收同比 | -4.4% | 17.1% |
| 净利润同比 | 56.9% | — |
| 每股收益（稀释后） | $0.20 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCKTZLAB
| Q4 25 | $75.8M | $127.1M | ||
| Q3 25 | $73.1M | $115.4M | ||
| Q2 25 | $78.9M | $109.1M | ||
| Q1 25 | $77.9M | $105.7M | ||
| Q4 24 | $79.2M | $108.5M | ||
| Q3 24 | $79.8M | $101.8M | ||
| Q2 24 | $77.7M | $100.1M | ||
| Q1 24 | $77.2M | $87.1M |
净利润HCKTZLAB
| Q4 25 | $5.6M | — | ||
| Q3 25 | $2.5M | $-36.0M | ||
| Q2 25 | $1.7M | $-40.7M | ||
| Q1 25 | $3.1M | $-48.4M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $8.6M | $-41.7M | ||
| Q2 24 | $8.7M | $-80.3M | ||
| Q1 24 | $8.7M | $-53.5M |
毛利率HCKTZLAB
| Q4 25 | 41.7% | 51.0% | ||
| Q3 25 | 40.7% | 59.5% | ||
| Q2 25 | 35.4% | 60.6% | ||
| Q1 25 | 35.8% | 63.6% | ||
| Q4 24 | 39.4% | 61.5% | ||
| Q3 24 | 29.2% | 64.1% | ||
| Q2 24 | 27.5% | 64.9% | ||
| Q1 24 | 26.2% | 61.4% |
营业利润率HCKTZLAB
| Q4 25 | 12.0% | -54.6% | ||
| Q3 25 | 7.5% | -42.3% | ||
| Q2 25 | 5.8% | -50.3% | ||
| Q1 25 | 5.7% | -53.3% | ||
| Q4 24 | 9.8% | -62.6% | ||
| Q3 24 | 16.0% | -66.6% | ||
| Q2 24 | 16.1% | -76.0% | ||
| Q1 24 | 14.9% | -80.7% |
净利率HCKTZLAB
| Q4 25 | 7.4% | — | ||
| Q3 25 | 3.5% | -31.2% | ||
| Q2 25 | 2.1% | -37.3% | ||
| Q1 25 | 4.0% | -45.8% | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 10.8% | -40.9% | ||
| Q2 24 | 11.3% | -80.2% | ||
| Q1 24 | 11.3% | -61.4% |
每股收益（稀释后）HCKTZLAB
| Q4 25 | $0.20 | $-0.05 | ||
| Q3 25 | $0.09 | $-0.03 | ||
| Q2 25 | $0.06 | $-0.04 | ||
| Q1 25 | $0.11 | $-0.04 | ||
| Q4 24 | $0.11 | $-0.09 | ||
| Q3 24 | $0.31 | $-0.04 | ||
| Q2 24 | $0.31 | $-0.08 | ||
| Q1 24 | $0.32 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $68.1M | $715.5M |
| 总资产 | $206.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HCKTZLAB
| Q4 25 | $18.2M | $689.6M | ||
| Q3 25 | $13.9M | $717.2M | ||
| Q2 25 | $10.1M | $732.2M | ||
| Q1 25 | $9.2M | $757.3M | ||
| Q4 24 | $16.4M | $779.7M | ||
| Q3 24 | $10.0M | $616.1M | ||
| Q2 24 | $19.1M | $630.0M | ||
| Q1 24 | $13.0M | $650.8M |
股东权益HCKTZLAB
| Q4 25 | $68.1M | $715.5M | ||
| Q3 25 | $101.6M | $759.9M | ||
| Q2 25 | $119.8M | $791.7M | ||
| Q1 25 | $114.4M | $810.8M | ||
| Q4 24 | $115.6M | $840.9M | ||
| Q3 24 | $110.9M | $667.7M | ||
| Q2 24 | $102.2M | $704.2M | ||
| Q1 24 | $93.5M | $762.2M |
总资产HCKTZLAB
| Q4 25 | $206.4M | $1.2B | ||
| Q3 25 | $200.7M | $1.2B | ||
| Q2 25 | $200.5M | $1.2B | ||
| Q1 25 | $191.8M | $1.2B | ||
| Q4 24 | $193.3M | $1.2B | ||
| Q3 24 | $190.8M | $985.3M | ||
| Q2 24 | $187.5M | $987.4M | ||
| Q1 24 | $179.3M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.41× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流HCKTZLAB
| Q4 25 | $19.1M | $-26.0M | ||
| Q3 25 | $11.4M | $-32.0M | ||
| Q2 25 | $5.6M | $-31.0M | ||
| Q1 25 | $4.2M | $-61.7M | ||
| Q4 24 | $20.6M | $-55.8M | ||
| Q3 24 | $10.6M | $-26.8M | ||
| Q2 24 | $13.7M | $-42.2M | ||
| Q1 24 | $2.8M | $-90.1M |
自由现金流HCKTZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | $3.7M | $-33.9M | ||
| Q1 25 | $2.6M | $-63.2M | ||
| Q4 24 | $19.6M | $-58.4M | ||
| Q3 24 | $9.3M | $-28.2M | ||
| Q2 24 | $12.8M | $-42.9M | ||
| Q1 24 | $1.8M | $-91.1M |
自由现金流率HCKTZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | 4.7% | -31.1% | ||
| Q1 25 | 3.4% | -59.9% | ||
| Q4 24 | 24.8% | -53.8% | ||
| Q3 24 | 11.7% | -27.7% | ||
| Q2 24 | 16.5% | -42.9% | ||
| Q1 24 | 2.4% | -104.5% |
资本支出强度HCKTZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.2% | 1.1% |
现金转化率HCKTZLAB
| Q4 25 | 3.41× | — | ||
| Q3 25 | 4.47× | — | ||
| Q2 25 | 3.40× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 5.79× | — | ||
| Q3 24 | 1.23× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 0.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCKT
| Global S And BT | $39.1M | 52% |
| Sap Solutions | $22.4M | 30% |
| Consulting And Software Support And Maintenance | $14.3M | 19% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
